Besides, a combined treatment with AKT inhibitor and ADARB1 knockdown obviously resulted in much slower proliferation rates of TMZ-resistant glioma cells, indicating that ADARB1 might be involved in AKT-mediated TMZ resistance of glioma cells. The gene discussed is ADARB1; the disease is glioma.